Recent Press Releases

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease

Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of...

Liftstream Report Finds Ten Men for Every Woman Present in Biotech Boardrooms

Unstructured hiring practices and over-reliance on personal networks is limiting opportunities for women in biotech Germany and The Netherlands have the lowest proportion of women in the boardroom...

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments

ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments Reserved capital increased with €30 million, of...

Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin

Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin -- Relamorelin is a Novel Peptide Ghrelin Agonist for Diabetic Gastroparesis ---- Actavis Option to...

Forendo Pharma closes EUR 12 million Series A financing round to develop a novel targeted therapy for endometriosis

Turku, Finland--Forendo Pharma today announced the successful closing of a EUR 12 million new investment round. Novartis Venture Fund and MS Ventures will participate in the financing round,...

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine Published: Oct 23, 2014 (Thomson Reuters ONE via...

LEADING RESEARCHERS JOIN BIOGEN IDEC TO ADVANCE DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

–Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort– CAMBRIDGE, Mass., October 23, 2014, Biogen Idec (NASDAQ: BIIB)...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

INDIANAPOLIS and VANCOUVER, British Columbia -- Eli Lilly and Company (NYSE: LLY) and Zymeworks Inc. today announced the expansion of their existing licensing and collaboration agreement. Originally...

Johnson & Johnson Innovation Announces New J-Labs Incubator at Texas Medical Center

J-Labs @TMC Will Be a Core Component of the Texas Medical Center's Innovation Institute HOUSTON, October 23, 2014 -- Johnson & Johnson Innovation, LLC., today announced plans to expand...

Sutro Biopharma and Celgene Corporation Enter Multi-Year Strategic Collaboration and Option to Acquire Agreement

Deal Expands Immuno-Oncology Product Discovery and Development Program and Aims to Accelerate Development of Oncology Therapeutics with Compelling Patient Benefit SOUTH SAN FRANCISCO, Oct 23, 2014...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

Viamet Announces $60 Million Series D Financing

RESEARCH TRIANGLE PARK, N.C., Oct 21, 2014 (BUSINESS WIRE) -- Viamet Pharmaceuticals Holdings, LLC (Viamet) today announced the closing of a $60 million Series D financing provided by Brandon Point...

Roche invests for the future in its Basel site

Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented development plans for its Basel site. Over the...

A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - - Conference Call Today at 8:30 a.m. EDT to Discuss Results - LA...

Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production

New Brunswick, N.J., (Oct. 22, 2014) – Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 -- The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release...

RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting...